HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marie-Laure Risse Selected Research

carfilzomib

3/2024Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
10/2023Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.
9/2023Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
1/2023Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
1/2023Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
1/2023Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis.
1/2023Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.
12/2022Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.
12/2022Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
11/2022Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marie-Laure Risse Research Topics

Disease

17Multiple Myeloma
03/2024 - 05/2018
4Residual Neoplasm
03/2024 - 01/2022
2Neoplasms (Cancer)
01/2021 - 10/2003
1Disease Progression
03/2024
1Chromosome Aberrations (Chromosome Abnormalities)
03/2024
1Urinary Bladder Neoplasms (Bladder Cancer)
01/2013
1Stomach Neoplasms (Stomach Cancer)
11/2006

Drug/Important Bio-Agent (IBA)

17isatuximabIBA
03/2024 - 05/2018
16Dexamethasone (Maxidex)FDA LinkGeneric
03/2024 - 05/2018
15carfilzomibIBA
03/2024 - 01/2020
3Monoclonal AntibodiesIBA
12/2022 - 01/2021
2pomalidomideIBA
01/2021 - 05/2018
2Proteins (Proteins, Gene)FDA Link
01/2021 - 01/2021
2Cisplatin (Platino)FDA LinkGeneric
01/2013 - 11/2006
1Adenosine Monophosphate (AMP)IBA
03/2024
1antineoplaston A10 (A 10)IBA
01/2022
1GemcitabineFDA Link
01/2013
1larotaxelIBA
01/2013
1thiamine triphosphorate (TTP)IBA
11/2006
1Fluorouracil (Carac)FDA LinkGeneric
11/2006
1Docetaxel (Taxotere)FDA Link
11/2006
1Irinotecan (Camptosar)FDA LinkGeneric
10/2003

Therapy/Procedure

8Therapeutics
03/2024 - 11/2006
1Transplantation
01/2023
1Intravenous Infusions
10/2003